Category: Shire Plc.Syndicate content

Shire ditches troubled Dermagraft skin substitute

January 20, 2014 by Arezu Sarvestani

Ireland-based Shire plc signs a definitive agreement to divest its beleaguered Dermagraft skin substitute, handing the business over to Organogenesis in a deal worth up to $300 million.

Shire ditches troubled Dermagraft skin substitute

Regenerative therapies maker Shire (NSDQ:SHPGY) announced that it sold its troubled Dermagraft business to Organogenesis in a deal worth up to $300 million in sales-based milestone payments.

MIT and Children's Medical sue Shire over DermaGraft diabetic foot ulcer treatment

January 18, 2013 by MassDevice staff

Massachusetts Institute of Technology and Children's Hospital Corp. accuse Shire Regenerative Medicine of willfully infringing on a trio of patents with its DermaGraft diabetic foot ulcer skin graft treatment.

legal gavel

Regenerative therapies maker Shire (NSDQ:SHPGY) found itself the focus of a lawsuit after the Massachusetts Institute of Technology and Children's Medical Center Corp. accused the company of willfully infringing on a trio of patents.

Shire expands regenerative medicine biz with Lotus Tissue Repair acquisition

January 10, 2013 by MassDevice staff

British pharma player Shire expands its regenerative medicine footprint with the acquisition of Lotus Tissue Repair, which focuses on the treatment of the genetic disease dystrophic epidermolysis bullosa.

Shire

Shire (NSDQ:SHPGY) said it aquired Cambridge, Mass.-based Lotus Tissue Repair, which is developing the 1st protein replacement therapy to treat dystrophic epidermolysis bullosa, a rare genetic disease.

The purchase includes an upfront payment and later milestone payments, but specific details were not released.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Shire wins DermaGraft nod in Canada

September 5, 2012 by MassDevice staff

Health Canada approves the DermaGraft regenerative skin patch for patients with diabetic foot ulcers.

Shire

Regulators north of the border gave Shire (NSDQ:SHPGY) its first approval outside of the U.S. for the DermaGraft regenerative skin patch it bought when it acquired Advanced BioHealing last year.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Venture capital: Medical device "Big Exits" on the rise | Wall Street Beat

July 23, 2012 by MassDevice staff

Venture-backed "Big Exits" in the medical device industry were higher in 2011 than for the 4 years prior.

MassDevice.com Wall Street Beat

Venture-backed M&A activity in 2011 was higher than any other year since 2005, according to a new report tracking trends in lifesciences.

The medical device industry in 2011 had 18 "Big Exits," defined as venture-backed acquisitions where the up-front payment totaled $75 million or more.

Shire bets big on regenerative medicine, eyeing a $1B return | Wall Street Beat

June 18, 2012 by MassDevice staff

Shire puts more skin in regenerative medicine with a $100 million facility expansion in San Diego that it hopes will turn into a billion-dollar business within the decade.

MassDevice.com Wall Street Beat

Shire (NSDQ:SHPGY) has high hopes for its regenerative medicine units, aiming to forge a $1 billion business within the decade.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Diabetes: DOJ investigates Shires' DermaGraft marketing

April 26, 2012 by MassDevice staff

Shire faces civil and criminal investigations by the U.S. Justice Dept. and a pair of U.S. Attorneys' Offices for marketing practices related to its DermaGraft diabetic foot ulcer treatment.

Shire plc logo

British biotech Shire (NSDQ:SHPGY) is under investigation by the U.S. Justice Dept. for marketing practices for its Dermagraft diabetic foot ulcer treatment, according to regulatory filings.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp